share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K:重大事件
美股SEC公告 ·  2024/05/11 04:51

Moomoo AI 已提取核心信息

TransCode Therapeutics, Inc., a biotech company, has announced its intention to appeal a delisting notice from the Nasdaq Stock Market. The company received the notice on May 7, 2024, indicating that it had failed to comply with the Nasdaq's Minimum Bid Price Rule by not maintaining a minimum closing bid price of $1.00 per share. TransCode Therapeutics was given until May 6, 2024, to regain compliance but was unable to meet the requirement. Additionally, the company did not meet the $5,000,000 minimum stockholders' equity requirement for initial listing on The Nasdaq Capital Market. The company plans to request a hearing before a Nasdaq Hearings Panel by May 14, 2024, to address the deficiencies and present a plan to regain compliance. Until the hearing process concludes, the company's common stock will remain listed and eligible for trading on Nasdaq. However, there is no guarantee that TransCode Therapeutics will be able to regain compliance and avoid delisting.
TransCode Therapeutics, Inc., a biotech company, has announced its intention to appeal a delisting notice from the Nasdaq Stock Market. The company received the notice on May 7, 2024, indicating that it had failed to comply with the Nasdaq's Minimum Bid Price Rule by not maintaining a minimum closing bid price of $1.00 per share. TransCode Therapeutics was given until May 6, 2024, to regain compliance but was unable to meet the requirement. Additionally, the company did not meet the $5,000,000 minimum stockholders' equity requirement for initial listing on The Nasdaq Capital Market. The company plans to request a hearing before a Nasdaq Hearings Panel by May 14, 2024, to address the deficiencies and present a plan to regain compliance. Until the hearing process concludes, the company's common stock will remain listed and eligible for trading on Nasdaq. However, there is no guarantee that TransCode Therapeutics will be able to regain compliance and avoid delisting.
生物技术公司TransCode Therapeutics, Inc. 宣布打算对纳斯达克股票市场的退市通知提出上诉。该公司于2024年5月7日收到通知,表明它没有维持每股1.00美元的最低收盘价,从而未能遵守纳斯达克的最低出价规则。TransCode Therapeutics在2024年5月6日之前获准恢复合规,但未能满足要求。此外,该公司未达到在纳斯达克资本市场首次上市的500万美元最低股东权益要求。该公司计划在2024年5月14日之前要求纳斯达克听证会小组举行听证会,以解决缺陷并提出恢复合规的计划。在听证会结束之前,该公司的普通股将继续上市并有资格在纳斯达克交易。但是,无法保证TransCode Therapeutics能够恢复合规并避免退市。
生物技术公司TransCode Therapeutics, Inc. 宣布打算对纳斯达克股票市场的退市通知提出上诉。该公司于2024年5月7日收到通知,表明它没有维持每股1.00美元的最低收盘价,从而未能遵守纳斯达克的最低出价规则。TransCode Therapeutics在2024年5月6日之前获准恢复合规,但未能满足要求。此外,该公司未达到在纳斯达克资本市场首次上市的500万美元最低股东权益要求。该公司计划在2024年5月14日之前要求纳斯达克听证会小组举行听证会,以解决缺陷并提出恢复合规的计划。在听证会结束之前,该公司的普通股将继续上市并有资格在纳斯达克交易。但是,无法保证TransCode Therapeutics能够恢复合规并避免退市。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息